Mylan, a group from Pittsburgh (USA) wants to acquire Rottapharm, a Lombard company owned by the Rovati family which, according to some estimates, could be worth around 2 billion euros. The Italian company, which has been the object of the unsuccessful interest of the funds private equity like Avista, Carlyle and Clessidra, could take a different direction: not financial partners, but a pharmaceutical giant, like the American one, with a turnover of 5.5 billion dollars and a market capitalization of around 10 billion.
(Il Sole 24 Ore Pag.31 – 29/02/2012) 
